Cullinan Therapeutics Inc.

This is an early-stage study testing the safety and initial effectiveness of a new drug called CLN-619. It is being given to adults with advanced solid tumors that have spread or cannot be removed by surgery. Researchers are testing CLN-619 by itself and combined with other appro…

This early-stage study is testing the safety and initial effectiveness of an experimental antibody called CLN-619 in adults with multiple myeloma that has returned and stopped responding to standard treatments. The main goals are to find a safe dose and see if the treatment can s…